Delving into the Latest Updates on Autologous adipose-derived mesenchymal stem cell therapy (Cellular Biomedicine Group) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

Adiposederived mesenchymal progenitor cell therapy Cellular Biomedicine Group, Autologous haMPC therapy Cellular Biomedicine Group, Re-Join

+ [1]

Target-

Action-

Mechanism

Cell replacements

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal Diseases

Active Indication-

Inactive Indication

Osteoarthritis, Knee

Originator Organization

Shanghai Jiao Tong University

AbelZeta Pharma, Inc.

Active Organization-

Inactive Organization

AbelZeta Pharma, Inc.

License Organization-

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Current medication treatments for KOA aim to relieve inflammation and pain, but they do little to delay or reverse the disease progression and most medications have obvious side effects. When the conservative treatments are useless to patients and joint deformities and joint disfunction, the patients may require surgery. Although surgery of the joints can relieve the pain temporarily, long-term effect (over 10 years) is hard to achieve.

Start Date01 Nov 2013

Sponsor / Collaborator

AbelZeta Pharma, Inc.

[+1]

NCT01809769

/ CompletedPhase 1/2

Autologous Adipose Tissue Derived Mesenchymal Stem Cells Therapy for Patients With Knee Osteoarthritis by Intra-articular Injection: A PhaseⅠ/Ⅱa, Randomized and Double-blinded Clinical Trial

Two injections in total and 3 ml autologous adipose-tissue-derived stem cells(haMSCs) for each injection; time-points for intervention: 1) initial injection; 2) 3 weeks following initial injection.

Start Date01 Mar 2013

Sponsor / Collaborator

Shanghai Cellular Biopharmaceutical Group Ltd.

[+1]

100 Clinical Results associated with Autologous adipose-derived mesenchymal stem cell therapy (Cellular Biomedicine Group)

Login to view more data

100 Translational Medicine associated with Autologous adipose-derived mesenchymal stem cell therapy (Cellular Biomedicine Group)

Login to view more data

100 Patents (Medical) associated with Autologous adipose-derived mesenchymal stem cell therapy (Cellular Biomedicine Group)

Login to view more data

2

Literatures (Medical) associated with Autologous adipose-derived mesenchymal stem cell therapy (Cellular Biomedicine Group)

01 Jan 2020·Regenerative medicineQ4 · ENGINEERING & TECHNOLOGY

Human Adipose-Derived Mesenchymal Progenitor Cells Plus Microfracture and Hyaluronic Acid for Cartilage Repair: A Phase IIa Trial

Q4 · ENGINEERING & TECHNOLOGY

Article

Author: Qiao, Zhiguang ; Yue, Bing ; Li, Meng ; Dai, Chengxiang ; Wang, Jinwu ; Xuan, Liang ; Li, Suke ; Xu, Cuili ; Zhang, Jun ; Tang, Jiaxin ; Wang, You ; Dai, Kerong

Aim: This study aimed to preliminarily evaluate the safety and efficacy of human adipose-derived mesenchymal progenitor cells (haMPCs) in combination with microfracture and hyaluronic acid (HA) for treating cartilage defects. Materials & methods: A total of 30 patients with medial femoro-tibial condylar cartilage defects were randomized into three groups: arthroscopic microfracture group and normal saline injection, arthroscopic microfracture and intra-articular injection of HA, or arthroscopic microfracture in combination with intra-articular injection of HA and haMPCs. Results & conclusions: The data demonstrated that intra-articular injection of haMPCs plus microfracture and HA is a safe procedure to improve joint function in patients with knee cartilage defects. These findings provide an impetus for future research on this treatment. ClinicalTrials.gov Identifier: NCT02855073

01 Dec 2019·Stem cell research & therapyQ2 · MEDICINE

Treatment of knee osteoarthritis with intra-articular injection of autologous adipose-derived mesenchymal progenitor cells: a prospective, randomized, double-blind, active-controlled, phase IIb clinical trial

Q2 · MEDICINE

ArticleOA

Author: Dai, Chengxiang ; Fu, Qiong ; Zhang, Zhongwen ; Ye, Ping ; Zhao, Dongbao ; Zhang, Li ; Dong, Yuru ; Li, Suke ; Bao, Chunde ; Wu, Xiaojing ; Song, Yang ; Lu, Liangjing ; Du, Hui ; Pang, Yafei

OBJECTIVE:

Human adipose-derived mesenchymal progenitor cells (haMPCs) are stem cells with multiple differentiation potential and immunomodulatory function. Re-Join® comprises in vitro expanded haMPCs from adipose tissue of patients combined with cell suspension solution. This study was undertaken to evaluate the efficacy and safety of Re-Join® in patients with symptomatic knee osteoarthritis (OA).

METHODS:

Patients with Kellgren-Lawrence grade 1-3 knee OA were recruited from two centers and randomized to receive intra-articular injection of Re-Join® or HA. Pain and function were assessed by using WOMAC score, VAS, and SF-36. Magnetic resonance imaging (MRI) analysis was performed to measure cartilage repair. Adverse events (AEs) were collected.

RESULTS:

Fifty-three patients were randomized. Significant improvements in WOMAC, VAS, and SF-36 scores were observed in both groups at months 6 and 12 compared with baseline. Compared with the HA group, significantly more patients achieved 50% improvement of WOMAC and a trend of more patients achieved a 70% improvement rate in Re-Join® group after 12 months. Meanwhile, there was notably more increase in articular cartilage volume of both knees in the Re-Join® group than in the HA group after 12 months as measured by MRI. AEs were comparable between two groups. Most AEs were mild and moderate except one SAE of right knee joint infection in the HA group.

CONCLUSIONS:

Significant improvements in joint function, pain, quality of life, and cartilage regeneration were observed in Re-Join®-treated knee OA patients with good tolerance in a period of 12 months.

TRIAL REGISTRATION:

ClinicalTrials.gov Identifier: NCT02162693 . Registered 13 June 2014.

100 Deals associated with Autologous adipose-derived mesenchymal stem cell therapy (Cellular Biomedicine Group)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteoarthritis, Knee	Phase 2	China	AbelZeta Pharma, Inc.	01 Nov 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02855073 (Pubmed \| Regen Med) Manual	Phase 2	Cartilage Injury	30	BDDE cross-linked sodium hyaluronate gel+Human adipose-derived mesenchymal progenitor cells	sctcqbywkh(sqohkfzudi) = No serious AEs were observed in this study. wpmyvgyczm (ujjnxryhsc )	Positive	01 Jan 2020